News Releases | Investor Relations

Date	Title
02/14/17	Summary Toggle PLx Pharma Announces Publication of Positive Antiplatelet Data for Aspertec in Peer-Reviewed Medical Journal JACC HOUSTON, Feb. 14, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLx), a late-stage specialty pharmaceutical company developing next-generation nonsteroidal anti-inflammatory drugs and other pharmaceutical agents today announced that	PDF Version
12/22/16	Summary Toggle PLx Pharma and Dipexium Announce Merger Agreement NEW YORK and HOUSTON, Dec. 22, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ) and PLx Pharma Inc.	PDF Version
03/15/16	Summary Toggle Mike Valentino Named Recipient of Ivan D. Combe Lifetime Achievement Award HOUSTON (January 4, 2016) – PLx Pharma Inc. (PLx), a privately-held, late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products, announces that Natasha Giordano has been appointed as ...	PDF Version
11/16/10	Summary Toggle Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial Relative contributions of local and systemic mechanisms of upper gastrointestinal (GI) injury following aspirin are unknown. Studies suggest that aspirin’s GI risk is age related and that gastroprotection may be needed at therapy initiation.	PDF Version
06/09/08	Summary Toggle Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients Background Chronic use of NSAIDs is associated with gastrointestinal (GI) toxicity that increases with age. Aim To evaluate the GI safety and therapeutic efficacy of ibuprofen chemically associated with phosphatidylcholine (PC) in osteoarthritic (OA) patients.	PDF Version